Alliance Pharma (LON:APH)‘s stock had its “buy” rating reiterated by equities researchers at Numis Securities in a report released on Friday, December 1st, Marketbeat reports. They currently have a GBX 66 ($0.88) price objective on the stock, down from their prior price objective of GBX 71 ($0.95). Numis Securities’ price objective indicates a potential downside of 1.68% from the company’s previous close.

A number of other research analysts have also commented on the stock. FinnCap restated a “buy” rating and issued a GBX 58 ($0.78) price objective on shares of Alliance Pharma in a research note on Tuesday, November 21st. N+1 Singer restated a “not rated” rating on shares of Alliance Pharma in a research note on Wednesday, September 13th. Finally, Investec began coverage on shares of Alliance Pharma in a research note on Wednesday, September 13th. They issued a “buy” rating and a GBX 59 ($0.79) price objective on the stock.

Alliance Pharma (LON:APH) traded up GBX 0.62 ($0.01) during midday trading on Friday, reaching GBX 67.13 ($0.90). 497,587 shares of the company’s stock were exchanged, compared to its average volume of 223,064. The firm has a market capitalization of $303.56 and a price-to-earnings ratio of 1,342.50. Alliance Pharma has a one year low of GBX 44.75 ($0.60) and a one year high of GBX 64 ($0.86).

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at

About Alliance Pharma

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.

Receive News & Ratings for Alliance Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma and related companies with's FREE daily email newsletter.